Review of DPP-4 inhibitors explores novel therapeutic applications beyond diabetes, including cardiovascular protection, neurodegeneration, and inflammatory conditions.
Key findingReview of DPP-4 inhibitors explores novel therapeutic applications beyond diabetes, including cardio
What the researchers found
Review of DPP-4 inhibitors explores novel therapeutic applications beyond diabetes, including cardiovascular protection, neurodegeneration, and inflammatory conditions.
Why it matters
Relevant to peptide-based therapeutic applications.
The numbers in context
Review covers six DPP-4 inhibitors: sitagliptin, vildagliptin, saxagliptin, linagliptin, alogliptin, and teneligliptin.
How the study worked
Methodology in publication.
Who was studied
Adults with type 2 diabetes across DPP-4 inhibitor clinical trials
What this study cannot tell us
Limitations in publication.
How to read the evidence
Based on study design.
When this study was published
Published in 2025.
The bigger picture
Contributes to peptide therapeutic evidence.
Questions still open
- Long-term implications?
- Comparison to evidence?
- Next research?
Common questions
What does this mean?
How reliable?
Read the original research
Dipeptidyl Peptidase 4 Inhibitors: Novel Therapeutic Agents in the Management of Type II Diabetes Mellitus.
Pharmacoepidemiology and drug safety, 34(12), e70277
Citation
Aloke, Chinyere; Adelusi, Oluwasola Abayomi; Onisuru, Olalekan Olugbenga; Iwuchukwu, Emmanuel Amarachi; Achilonu, Ikechukwu. (2025). Dipeptidyl Peptidase 4 Inhibitors: Novel Therapeutic Agents in the Management of Type II Diabetes Mellitus.. Pharmacoepidemiology and drug safety, 34(12), e70277. https://doi.org/10.1002/pds.70277